Accenture (NYSE:ACN) today announced it will work with
BioCelerate, a subsidiary of TransCelerate BioPharma Inc., a
nonprofit focused on improving efficiencies in research and
development, to develop a platform enabling its member companies to
aggregate and analyze preclinical and clinical information to
improve drug development efficiency and bring new medicines to
patients faster.
“The ability to collect and leverage large amounts of
precompetitive information to create new insights in the R&D
process is an important development in the preclinical research
space, said Kevin Julian, senior managing director, Accenture Life
Sciences North America and Accelerated R&D Services. “We are
eager to collaborate with BioCelerate on this critical initiative
to further enable the sharing of data to maximize the value of
preclinical and clinical research and deliver better patient
outcomes.”
The R&D data sharing platform will be built on the Accenture
Insights Platform. The Accenture
Insights Platform provides a portfolio of advanced analytics
capabilities, and an integrated design, build, run environment, to
enable the development of industry and function-specific analytics
solutions.
The platform will provide participating member companies the
ability to assimilate, aggregate, and analyze de-identified
preclinical and clinical information, enabling them to draw their
respective conclusions from a large data set. The platform will be
used initially to support BioCelerate’s first collaborative
project, Toxicology & Background Control Data Sharing, to
enhance product safety.
”Sharing preclinical data among the BioCelerate member companies
can be a powerful tool for improving drug discovery and
development. With this initiative, BioCelerate members will be able
to make more informed decisions on compound progression based on a
better understanding of preclinical safety data,” said Mike
Graziano Ph.D., DABT, Vice President of Drug Safety Evaluation at
BMS and lead for the BioCelerate initiative.
Dalvir Gill, Ph.D. CEO of TransCelerate BioPharma, Inc. said:
“Accenture’s deep expertise in life sciences, digital, analytics,
and clinical data-related services will be instrumental in
delivering this new platform and builds on the multi-year
relationship between Accenture and TransCelerate. All BioCelerate
member companies recently signed a collaborative Data Sharing
Agreement outlining the guidelines of the data that will be shared
across companies. This, along with selecting Accenture to build and
host the global data sharing platform, marks another significant
milestone in advancing the industry. We are truly excited for the
long-term strategic vision of this platform and envisage a future
whereby drug developers can connect preclinical, clinical and other
data types within the same data sharing platform.”
Following launch of the platform, data from TransCelerate’s
Placebo Standard of Care Data Sharing (PSoC) initiative will be
migrated, creating the foundation for additional preclinical and
clinical data sharing across member companies. The PSoC initiative
was established to maximize the value of historic clinical data
collected during clinical trials, and was the first
cross-therapeutic, multi-sponsor clinical data sharing initiative
of its kind designed to improve trial design and safety
surveillance.
In October 2015, Accenture was selected by TransCelerate to
support its PSoC initiative which has converted data for over 80
trials and more than 67,000 patients across seven therapeutic areas
such as Alzheimer’s, cardiovascular disease, and diabetes.
About Accenture
Accenture is a leading global professional services company,
providing a broad range of services and solutions in strategy,
consulting, digital, technology and operations. Combining unmatched
experience and specialized skills across more than 40 industries
and all business functions – underpinned by the world’s largest
delivery network – Accenture works at the intersection of business
and technology to help clients improve their performance and create
sustainable value for their stakeholders. With approximately
401,000 people serving clients in more than 120 countries,
Accenture drives innovation to improve the way the world works and
lives. Visit us at www.accenture.com.
About BioCelerate
BioCelerate, a subsidiary of TransCelerate BioPharma Inc.,
focuses on the identification and development of pragmatic and
tangible solutions to improve efficiencies in preclinical research,
with the end goal of improving overall drug development efficiency
to bring new medicines to patients faster. By actively
collaborating with participating TransCelerate Member Companies and
other industry stakeholders, BioCelerate leverages collective
knowledge to tackle areas of common challenge and unmet need in the
preclinical research space. The founding Member Companies are
Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company,
GlaxoSmithKline, Novo Nordisk and Shionogi & Co., Ltd.
About TransCelerate BioPharma, Inc.
TransCelerate BioPharma Inc. is a non-profit organization
dedicated to improving the health of people around the world by
simplifying and accelerating the research and development (R&D)
of innovative new therapies. The organizations' mission is to
collaborate across the global biopharmaceutical R&D community
to identify, prioritize, design and facilitate implementation of
solutions designed to drive the efficient, effective and high
quality delivery of new medicines. TransCelerate evolved from
conversations at various forums for executive R&D leadership to
discuss current issues facing the industry, and examine solutions
for addressing common challenges. The founding member companies are
AbbVie, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb,
Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson,
Pfizer, the Roche Group, and Sanofi. Additional members that have
joined since the inception of TransCelerate include Allergan, Inc.,
Amgen, Astellas Pharma Inc., EMD Serono, Inc. (a subsidiary of
Merck KGaA, Darmstadt, Germany), Merck & Co., Inc., Novo
Nordisk, Shionogi & Co., Ltd. and UCB.
Membership in TransCelerate is open to pharmaceutical and
biotechnology companies with Research & Development operations.
Executive offices are located in Philadelphia, PA. For more
information, please visit
http://www.transceleratebiopharmainc.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170410005102/en/
AccentureCam Granstra, + 1 312 693
5992cameria.l.granstra@accenture.comorBliss Integrated
CommunicationVicky Aguiar, + 1 212 584
5470vicky@blissintegrated.com
Accenture (NYSE:ACN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Accenture (NYSE:ACN)
Historical Stock Chart
From Apr 2023 to Apr 2024